Literature DB >> 7689445

Management of lower urinary tract infections.

R R Bailey1.   

Abstract

Most urinary tract infections (UTIs) present as bacterial cystitis in healthy women in the sexually active age group. The commonest pathogen is Escherichia coli and most of the remainder are due to Staphylococcus saprophyticus. Many women are prone to recurrent UTIs and these are invariably due to a reinfection with a different organism. After diagnosis, a curative course of treatment should be given, but the approach should be different if the infection is uncomplicated (normal urinary tract and normal renal function) as opposed to complicated (male patient, abnormal urinary tract, impaired host defence mechanisms, impaired renal function, infection with a virulent organism). It is believed that traditional dosage regimens for uncomplicated UTIs are extravagant. There is no convincing evidence that a long course of medication is more effective than a short one; in fact, the use of single dose therapy for uncomplicated UTIs is gaining support. Trimethoprim 600mg, cotrimoxazole (trimethoprim/sulfamethoxazole) 1.92g, fosfomycin trometamol 3g and the 4-quinolones are the preferred agents for single dose treatment. Failure of single dose therapy is a simple guide for the need for further urinary tract investigation or more intensive therapy. If UTIs recur, it may be necessary to consider long term, low dose prophylaxis. The most effective drugs for this type of treatment include nitrofurantoin 50mg, trimethoprim 100mg and norfloxacin 200mg, given at night. More recent studies show that a dose administered on alternate nights, 3 nights a week or after intercourse is just as effective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689445     DOI: 10.2165/00003495-199300453-00023

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  11 in total

Review 1.  An approach to evaluating antibacterial agents in the treatment of urinary tract infection.

Authors:  R H Rubin; T R Beam; W E Stamm
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

Review 2.  Brief overview of single-dose therapy for uncomplicated urinary tract infections.

Authors:  R R Bailey
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

3.  Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial.

Authors:  A Stapleton; R H Latham; C Johnson; W E Stamm
Journal:  JAMA       Date:  1990-08-08       Impact factor: 56.272

4.  Double blind, randomised trial comparing single dose enoxacin and trimethoprim for treatment of bacterial cystitis.

Authors:  R R Bailey; S I Gorrie; B A Peddie; P R Davies
Journal:  N Z Med J       Date:  1987-10-14

5.  Single-dose therapy for uncomplicated urinary tract infections.

Authors:  R R Bailey
Journal:  N Z Med J       Date:  1985-05-08

6.  Cost-benefit considerations in the management of uncomplicated urinary tract infections in sexually active women.

Authors:  R R Bailey
Journal:  N Z Med J       Date:  1987-11-11

7.  Prevention of recurrent urinary tract infections in postmenopausal women.

Authors:  M Privette; R Cade; J Peterson; D Mars
Journal:  Nephron       Date:  1988       Impact factor: 2.847

8.  Quinolones in the treatment of uncomplicated urinary tract infections.

Authors:  R R Bailey
Journal:  Int J Antimicrob Agents       Date:  1992-12       Impact factor: 5.283

9.  Management of recurrent urinary tract infections with patient-administered single-dose therapy.

Authors:  E S Wong; M McKevitt; K Running; G W Counts; M Turck; W E Stamm
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

Review 10.  Management of acute uncomplicated urinary tract infection in adults.

Authors:  T M Hooton; W E Stam
Journal:  Med Clin North Am       Date:  1991-03       Impact factor: 5.456

View more
  10 in total

Review 1.  Decision making, evidence, audit, and education: case study of antibiotic prescribing in general practice.

Authors:  T Lipman; D Price
Journal:  BMJ       Date:  2000-04-22

2.  Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species.

Authors:  Seung Young Kim; Kou-San Ju; William W Metcalf; Bradley S Evans; Tomohisa Kuzuyama; Wilfred A van der Donk
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 3.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 5.  Recurrent urinary tract infection in women: emerging concepts regarding etiology and treatment considerations.

Authors:  E Ann Gormley
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

6.  Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.

Authors:  Demetra Kavatha; Helen Giamarellou; Zoe Alexiou; Nickolas Vlachogiannis; Stavroula Pentea; Thomas Gozadinos; Garyphalia Poulakou; Agissilaos Hatzipapas; George Koratzanis
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women.

Authors:  G Elhanan; H Tabenkin; R Yahalom; R Raz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 8.  Biosynthesis of phosphonic and phosphinic acid natural products.

Authors:  William W Metcalf; Wilfred A van der Donk
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

9.  Stereoselective epoxidation of cis-propenylphosphonic acid to fosfomycin by a newly isolated bacterium Bacillus simplex strain S101.

Authors:  Fuhong Xie; Yapeng Chao; Zhiquan Xue; Xiuqing Yang; Guoqing Zhang; Jiaji Shi; Shijun Qian
Journal:  J Ind Microbiol Biotechnol       Date:  2009-03-04       Impact factor: 3.346

10.  Stereospecific Radical-Mediated B12-Dependent Methyl Transfer by the Fosfomycin Biosynthesis Enzyme Fom3.

Authors:  Martin I McLaughlin; Wilfred A van der Donk
Journal:  Biochemistry       Date:  2018-07-10       Impact factor: 3.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.